KMPH - KemPharm, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.15
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.15
Open5.20
Bid4.15 x 900
Ask5.45 x 1800
Day's Range5.05 - 5.25
52 Week Range2.45 - 8.40
Volume159,434
Avg. Volume139,765
Market Cap81.156M
Beta0.27
PE Ratio (TTM)N/A
EPS (TTM)-3.63
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.67
Trade prices are not sourced from all markets
  • KemPharm Stock Down Despite Positive Data on ADHD Candidate
    Zacks7 days ago

    KemPharm Stock Down Despite Positive Data on ADHD Candidate

    KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.

  • Groupon may be looking for a buyer, Boeing strikes major deal, KemPharm soars on drug test results
    Yahoo Finance Video8 days ago

    Groupon may be looking for a buyer, Boeing strikes major deal, KemPharm soars on drug test results

    Groupon, Boeing, KemPharm and Netflix are the companies to watch.

  • Benzinga8 days ago

    KemPharm's ADHD Candidate Meets Efficacy, Safety Trial Endpoints

    KemPharm Inc (NASDAQ: KMPH ) shares plunged nearly 7 percent off Monday’s open despite news that its KP415 candidate for ADHD met primary and secondary endpoints in a pivotal efficacy and safety trial. ...

  • Trump to reshape Supreme Court for decades to come
    Yahoo Finance Video8 days ago

    Trump to reshape Supreme Court for decades to come

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • MarketWatch8 days ago

    KemPharm's stock soars after ADHD drug trial meets primary endpoints

    MARKET PULSE Shares of KemPharm Inc. (kmph) shot up 13% in premarket trade Monday after the specialty pharmaceutical company said a trial of its treatment of ADHD in patients between the ages of 6 and 12 (KP415) met primary and secondary efficacy endpoints.

  • GlobeNewswire8 days ago

    KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD

    Results from Single Classroom-Style Trial Met Pre-Specified Primary and Secondary Endpoints. Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 8:00 a.m. ET. CORALVILLE, ...

  • Benzinga2 months ago

    Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst

    KemPharm Inc (NASDAQ: KMPH ) has struggled to gain traction since its 2015 initial public offering, but one long-sidelined analyst is ready for action. The Rating Janney analyst Ken Trbovich initiated ...

  • Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)?
    Simply Wall St.2 months ago

    Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)?

    In this article, I’m going to take a look at KemPharm Inc’s (NASDAQ:KMPH) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • Investopedia2 months ago

    KemPharm Stock Breaks Out on Clinical Trial Results

    KemPharm, Inc. ( KMPH) shares rose more than 10% by Friday afternoon after the company reported positive top-line results from the first of three pivotal human abuse clinical trials for KP415. The prodrug of d-methylphenidate for the treatment of attention deficit and hyperactivity disorder (ADHD) is designed to lower potential abuse compared with stimulant-based ADHD products, which could make it a go-to prescription within the multi-billion-dollar industry. In the clinical trial, researchers found that the prodrug was not readily converted into the active d-methylphenidate when injected, and as a result, it produced pharmacodynamic effects that were comparable to placebo endpoints.

  • Will KemPharm Inc’s (NASDAQ:KMPH) Earnings Grow Over The Next Few Years?
    Simply Wall St.2 months ago

    Will KemPharm Inc’s (NASDAQ:KMPH) Earnings Grow Over The Next Few Years?

    The latest earnings announcement KemPharm Inc’s (NASDAQ:KMPH) released in December 2017 showed that losses became smaller relative to the prrior year’s level – great news for investors Below, I’ve presentedRead More...

  • GlobeNewswire2 months ago

    KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET. Intravenous Human Abuse Potential Trial with KP415 Prodrug Clinical Findings:. Following intravenous ...

  • GlobeNewswire3 months ago

    KemPharm, Inc. to Report First Quarter 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for May 10, 2018, 4:30 p.m. ET. CORALVILLE, Iowa, May 01, 2018-- KemPharm, Inc., a specialty pharmaceutical company focused on the ...

  • ACCESSWIRE3 months ago

    Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

    Stock Monitor: KemPharm Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on VBI Vaccines Inc. (NASDAQ: VBIV ). If you want ...

  • Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH)
    Simply Wall St.4 months ago

    Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH)

    KemPharm Inc’s (NASDAQ:KMPH): KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The US$110.66M market-cap posted a loss in its most recentRead More...

  • ACCESSWIRE4 months ago

    KemPharm, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 29, 2018 / KemPharm, Inc. (NASDAQ: KMPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 29, 2018 at 4:30 PM Eastern Time. To ...

  • At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy?
    Simply Wall St.4 months ago

    At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy?

    KemPharm Inc (NASDAQ:KMPH), a pharmaceuticals company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a stock withRead More...

  • Market Exclusive5 months ago

    Here’s What’s Moving KemPharm And Puma Biotechnology

    KemPharm, Inc. (NASDAQ:KMPH) ran into the end of last week on news related to the company’s lead development program. At the close of trade on Friday, KemPharm shares were going for around six dollars apiece, up more than 13% on the day’s open. Premarket on Monday, shares rose again to $6.35 but have since settled […] The post Here’s What’s Moving KemPharm And Puma Biotechnology appeared first on Market Exclusive.

  • Reuters5 months ago

    KemPharm's opioid painkiller gets FDA approval, shares soar

    KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain, sending the shares of the drugmaker up as much as 36 percent in late afternoon trading. The company resubmitted the drug's marketing application for review in September after appealing against a rejection by the drug regulator in 2016 on concerns of opioid abuse. KemPharm said Apadaz is likely to be scheduled as a C-II product - a drug with a high potential for abuse.

  • Reuters5 months ago

    FDA approves KemPharm's opioid painkiller

    KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain. The FDA had said intranasal abuse of the opioid-based product was a relevant concern. KemPharm said the Drug Enforcement Administration (DEA) intends to schedule Apadaz as a C-II product.

  • Yahoo Finance Live: Market Movers - Jul 9th, 2018
    Yahoo Finance Video8 days ago

    Yahoo Finance Live: Market Movers - Jul 9th, 2018

    Yahoo Finance's LIVE stock market coverage and analysis.